4-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethyl)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethyl)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide
• 英文别名: 4-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethyl)-1-methyl-6-oxopyridine-3-carboxamide
• 化学式: C₁₅H₁₅FIN₃O₃
• 分子量: 431.205
• InChiKey: PFHWTBSZWRJPNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  81.7
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethyl)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide 、 2-丙炔-1-醇 在 碘化亚铜 、 双三苯基磷二氯化钯 TEA 、 silica gel 、 methanol-dichloromethane 作用下， 以 tetrahydrofuran N,N-dimethylformamide 为溶剂， 以to give 4-[2-fluoro-4-(3-hydroxy-1-propynyl)anilino]-N-(2-hydroxyethyl)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide as a cream solid (79%)的产率得到4-[2-fluoro-4-(3-hydroxy-1-propynyl)anilino]-N-(2-hydroxyethyl)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide
  参考文献：
  名称：

  5-Substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives

  摘要：

  本发明涉及5-取代-4-(取代)苯基氨基-2-吡啶酮衍生物、制药组合物及其使用方法。

  公开号：

  US20050026964A1
• 作为产物：
  描述：

  2,3,4,5,6-pentafluorophenyl 4-(2-fluoro-4-iodoanilino)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 、 C.I.酸性橙108 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以85%的产率得到4-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethyl)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide
  参考文献：
  名称：

  [EN] 5-SUBSTITUTED-4-`(SUBSTITUTED PHENYL)!AMINO!-2-PYRIDONE DEVIATIVES FOR USE AS MEK INHIBITORS
  [FR] DERIVES DE 4-[PHENYLAMINO (SUBSTITUE)]-2-PYRIDONE A SUBSTITUTION EN 5 EN TANT QU'INHIBITEURS DE LA MEK

  摘要：

  本发明涉及公式（I）的5-取代-4-(取代)苯胺基-2-吡啶酮衍生物，以及作为MEK抑制剂的药物组合物和使用方法。其中，公式（I）中W为公式（II）、公式（III）、公式（IV）或公式（V）；R1-5和Z如权利要求中所定义。

  公开号：

  WO2005000818A1

文献信息

• [EN] NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS<br/>[FR] NOUVEAUX DIESTERS PHOSPHORIQUES CYCLIQUES DE DIOLS DE 1,3-PROPANE-1-ARYLIQUES ET LEUR UTILISATION POUR LA PREPARATION DE PROMEDICAMENTS
  申请人：METABASIS THERAPEUTICS INC

  公开号：WO2004041834A2

  公开（公告）日：2004-05-21

  Compounds of Formula (I), their preparation and synthetic intermediates, and their use in the synthesis of prodrugs; wherein: V and L are trans relative to one another; V is selected from group consisting of carbocyclic aryl, substituted carbocyclic aryl, heteroaryl, and substituted heteroaryl; and L is a leaving group selected from the group consisting of halogen, alkyl sulfonate, aryloxy optionally substituted with 1-2 substituents, N-containing heteroaryl, and N-hydroxy-nitrogen containing heteroaryl; and salts thereof.

  公式（I）的化合物，其制备和合成中间体，以及它们在前药合成中的应用；其中：V和L相对于彼此是反式的；V选自群体，包括环烷基芳基，取代环烷基芳基，杂环芳基和取代杂环芳基；L是离去基，选自群体，包括卤素，烷基磺酸盐，取代1-2个取代基的芳氧基，含N的杂环芳基和含N-羟基-氮的杂环芳基；以及其盐。
• 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives
  申请人：Warner-Lambert Company, LLC

  公开号：US07273877B2

  公开（公告）日：2007-09-25

  The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

  本发明涉及5-取代-4-(取代)苯基氨基-2-吡啶酮衍生物、制药组合物以及使用方法。
• 4-Anilino-5-carboxamido-2-pyridone Derivatives as Noncompetitive Inhibitors of Mitogen-Activated Protein Kinase Kinase
  作者：Julie A. Spicer、Gordon W. Rewcastle、Michael D. Kaufman、Shannon L. Black、Mark S. Plummer、William A. Denny、John Quin、Aurash B. Shahripour、Stephen D. Barrett、Christopher E. Whitehead、Jared B. J. Milbank、Jeffrey F. Ohren、Richard C. Gowan、Charles Omer、Heidi S. Camp、Nadia Esmaeil、Kelley Moore、Judith S. Sebolt-Leopold、Sally Pryzbranowski、Ronald L. Merriman、Daniel F. Ortwine、Joseph S. Warmus、Cathlin M. Flamme、Alexander G. Pavlovsky、Haile Tecle

  DOI：10.1021/jm0704548

  日期：2007.10.1

  A new series of MEK1 inhibitors, the 4-anilino-5-carboxamido-2-pyridones, were designed and synthesized using a combination of medicinal chemistry, computational chemistry, and structural elucidation. The effect of variation in the carboxamide side chain, substitution on the pyridone nitrogen, and replacement of the 4'-iodide were all investigated. This study afforded several compounds which were either equipotent or more potent than the clinical candidate CI-1040 (1) in an isolated enzyme assay, as well as murine colon carcinoma (C26) cells, as measured by supression of phosphorylated ERK, substrate. Most notably, pyridone 27 was found to be more potent than I in vitro and produced a 100% response rate at a lower dose than 1, when tested for in vivo efficacy in animals bearing C26 tumors.
• NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP1556393A2

  公开（公告）日：2005-07-27
• US7273877B2
  申请人：——

  公开号：US7273877B2

  公开（公告）日：2007-09-25